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Abstract
Background: High expression levels of Inhibitors of Apoptosis Proteins (IAPs) have been correlated with poor
cancer prognosis and block the cell death pathway by interfering with caspase activation. SMAC-mimetics are
small-molecule inhibitors of IAPs that mimic the endogenous SMAC and promote the induction of cell death by
neutralizing IAPs.
Methods: In this study, anti-tumour activity of new SMAC-mimetics Birinapant and AT-406 is evaluated against
colorectal adenocarcinoma cells and IAP cross-talk with either oncogenic BRAF or BCL-2, or with the TRAIL are
further exploited towards rational combined protocols.
Results: It is shown that pre-treatment of SMAC-mimetics followed by their combined treatment with BRAF inhibitors
can decrease cell viability, migration and can very efficiently sensitize colorectal tumour cells to apoptosis. Moreover,
co-treatment of TRAIL with SMAC-mimetics can efficiently sensitize resistant tumour cells to apoptosis synergistically, as
shown by median effect analysis. Finally, Birinapant and AT-406 can synergise with BCL-2 inhibitor ABT-199 to reduce
viability of adenocarcinoma cells with high BCL-2 expression.
Conclusions: Proposed synergistic rational anticancer combined protocols of IAP antagonists Birinapant and AT-406 in
2D and 3D cultures can be later further exploited in vivo, from precision tumour biology to precision medical oncology.
Keywords: IAP antagonists, TRAIL, BRAF inhibitors, BCL2 inhibitors, Synergistic treatments, Overcome resistance in
colorectal cancer cells
Background
Colorectal cancer (CRC) is one of the most common malig-
nancies worldwide. Regarding pathophysiology, CRC devel-
opment is linked to the acquisition of oncogenic mutations.
In CRC, like in other tumour types, rational combination
treatments can overcome resistance.
Inhibitors of Apoptosis Proteins (IAPs), also known as
BIRCs (BIR domain containing proteins) are a class of
highly conserved proteins characterized by the presence
of Baculovirus IAP Repeat (BIR) domain, a Zn2+ ion co-
ordinating protein–protein interaction motif [1], pre-
dominantly known for the regulation of caspases and
immune signalling. These proteins are crucial for nu-
merous cellular signalling networks. There are eight
known mammalian IAPs/BIRCs; among them are cIAP-
1, cIAP-2, XIAP and SURVIVIN [1]. IAPs can be regu-
lated by certain endogenous inhibitors of IAPs like the
pro-apoptotic protein Second Mitochondria-Derived
Activator of Caspases (SMAC/DIABLO) [2–4], a mito-
chondrial protein released into the cytosol during apop-
totic induction [4].
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Although several studies have demonstrated elevated
levels of multiple IAPs in an array of human cancers,
there have been opposing prognostic implications for
IAPs in different tumour types, strongly suggesting that
the role of IAPs in tumorigenesis is context-and cell
type-dependent [5]. Apart from apoptotic-caspase cas-
cade, IAPs are essential modulators of innate immunity
signalling, canonical and non-canonical NF-kB pathways
as well as TGF-b signalling pathway [6]. Elevated expres-
sion of IAPs in certain tumour types has been correlated
with tumour survival and resistance to chemotherapy.
So, a variety of anti-tumour therapeutics, especially
small-molecule inhibitors against IAPs (IAP antagonist
compounds (IAC), SMAC-mimetics) are being designed
and clinically tested [7, 8]. Since targeting of IAPs can
be only partially efficient as anti-cancer therapy, rational
combination treatments with other targeted molecules
against driver oncogenes, or apoptotic factors can be
crucial to overcome tumour resistance.
BRAF is a proto-oncogene which encodes a serine/
threonine kinase and regulates the MAP kinase/ERK sig-
naling pathway, which is crucial for cell proliferation.
Mutations in this gene have been associated with various
cancers, including colorectal cancer (CRC) and display
potent transforming activity associated with progression
to metastasis [9]. PLX4032 (Vemurafenib) is a BRAF in-
hibitor which has demonstrated selectivity for the mu-
tated BRAFV600E compared to non-mutated BRAF
oncoprotein [10, 11]. PLX4032 was approved by the
FDA for the treatment of BRAF-mutated metastatic mel-
anoma [12]. Colorectal cancer and other cancer types
show intrinsic resistance to BRAFV600E specific inhibi-
tors, mainly due to feedback activation of EGFR. This is
treated with combined treatments that include BRAF
and EGFR inhibitors to achieve encouraging preclinical,
as well as clinical results [13].
Exploitation of TRAIL apoptotic properties for cancer
therapy has provided encouraging results in the last dec-
ade. TRAIL induces apoptosis via interacting with its
death receptors DR4 and DR5, which in turn results in
death-inducing signaling complex (DISC) formation and
caspase-8 processing [20]. Caspase-8 activation can then
result in caspase-3 activation through the mitochondrial-
independent pathway, and/or through the activation of
Bid through the mitochondrial-dependent pathway [21].
Moreover, many studies have shown that TRAIL is more
efficient in induction of cancer cell death in combined
treatments [22]. In recent studies, 5-Fluorouracil displayed
synergy with TRAIL in inducing apoptosis in mutant
KRAS non-small cell lung carcinoma cells [23]; TRAIL-
R2-specific antibodies and recombinant TRAIL can syner-
gise to kill cancer cells [24].
Targeting BCL-2 anti-apoptotic complexes and path-
ways in cancer is a productive drug discovery and
development field. The small molecule ABT-199, which
antagonizes the activity of BCL-2, is one of the most
promising examples being currently in clinical trials and
shows activity in many lymphoid malignancies as a sin-
gle agent and in combination with conventional chemo-
therapy agents [25, 26].
Apoptosis inhibition contributes to the survival and
proliferation of tumors and plays an important role to
current therapy resistance. Targeting apoptosis is there-
fore very promising for the development of new agents
that may enhance current cancer therapies. Birinapant
(TL32711), C42H56F2N8O6, is an antagonist of XIAP and
cIAP1 with Kd value of 45 nM and <1 nM, respectively
(Kd is the equilibrium constant involved in the dissoci-
ation of a compound into two or more compounds; the
lower the Kd value the higher the affinity of the com-
pound with the IAPs). Birinapant is a second-generation
bivalent antagonist of IAP proteins that is currently
undergoing clinical development for the treatment of
cancer. It has been demonstrated, using a range of assays
that evaluated cIAP1 stability and oligomeric state, that
Birinapant stabilized the cIAP1-BUCR (BIR3-UBA-
CARD-RING) dimer and promoted auto-ubiquitylation
of cIAP1 in vitro, and this improved tolerability has
allowed Birinapant to proceed into clinical studies [14].
The pro-apoptotic effects of Birinapant on caspase-3 ac-
tivation were evaluated in mice bearing 38C13 B-cell
lymphoma, HCT116 colon carcinoma or MDA-MB-231
breast adenocarcinoma tumours [15].
AT-406 (SM-406), C32H43N5O4, is a novel and orally
active antagonist of multiple IAP proteins (binds to
XIAP, cIAP1 and cIAP2). This is the first SMAC-
mimetic registered for clinical trials in patients with ad-
vanced cancer. Limited anti-tumour activity may suggest
development rather as adjunct treatment [16]. AT-406
acts as a strong radio sensitizer in human cervical cancer
cells [17] and has demonstrated anti-ovarian cancer effi-
cacy as a single agent and in combination with carbopla-
tin [18]. In addition, AT-406 is highly effective in
induction of apoptosis in xenograft tumours and is cur-
rently in phase I clinical trials for the treatment of of
solid and hematological human tumors [19].
In this study, we investigate the effect of IAPs inhib-
ition by recently developed SMAC-mimetics Birinapant
and AT-406 in colorectal tumour cells, their cross-talk
with the TRAIL-induced apoptotic pathway, BRAF and
BCL-2 oncogenic pathways and the underlying mecha-
nisms that can efficiently overcome tumour resistance
to apoptosis. Efficient protocols of inhibition of IAPs
activity and anti-apoptotic effect are presented by using
Birinapant or AT-406 alone and in their combinations
with either TRAIL or with other inhibitors of pro-
survival pathways, like BRAF-MEK and BCL-2. Syner-
gistic rational anticancer combined protocols are
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presented depending on the tumour cell background,
like resistance to individual treatments, BRAF mutation
or BCL-2 overexpression. These can be later further




DLD-1, HCT116, SW620, HT29, RKO, Colo-205 human
colon adenocarcinoma and Caco-2 colon intermediate ad-
enoma cell lines were obtained from American Type Cul-
ture Collection (ATCC). All cell lines used in this study
were grown in D-MEM medium supplemented with 10 %
Fetal Bovine Serum (#10270, ThermoFisher Scientific,
Wlatham, MA, USA, antibiotics (penicillin/streptomycin)
and amino acids. Cells were treated with the SMAC-
mimetics Debio1143 (or AT-406) and TL32711 (or Birina-
pant, catalog No. S7015, Shelleck Chemicals, Europe) that
block the interaction of IAPS with caspases. Cells were
also treated with the BRAFV600E inhibitor PLX-4720
(catalog No. S1152, Shelleck Chemicals, Europe), the
BCL-2 inhibitor ABT-199 (GDC-0199) (catalog No.
S8048, Shelleck Chemicals, Europe) and TRAIL SuperKil-
ler cc-TRAIL (ALX-522-020) (Alexis Biochemicals, Laus-
sane, Switzerland).
Western blotting
Whole cell lysates were prepared with RIPA Buffer
[50 mM Tris HCl pH: 8, 150 mM NaCl, 0.5 % sodium
deoxycholate, 1 % NP-40, 10 % SDS]. Extracts were re-
solved on SDS-PAGE, and transferred to nitrocellulose
membrane (Whatman, Scheicher & Schuell, Dassel,
Germany). Membranes were incubated with the specific
antibodies overnight at 4 °C, washed with TBS-Tween20
and incubated with the appropriate secondary antibody, for
1 h at room temperature. Antibodies were used against:
XIAP (1:500-#610716, BD Biosciences, San Jose, CA, USA),
cIAP-1 and cIAP-2 (1:750-/#sc-7943 and sc-7944, Santa
Cruz Biotechnology, Heidelberg, Germany), DR4 and DR5
(1:5000-/#1139 and #2019, ProSci Incorporated, Poway,
CA, USA),, FADD (1:1000-/#F36620, BD Biosciences, San
Jose, California, USA), BID (1:500-/#sc-11423, Santa Cruz
Biotechnology, Heidelberg, Germany), BAD (1:200-/#sc-
941, Santa Cruz Biotechnology, Heidelberg, Germany),
BAX (1:500-/#MS-711, ThermoFisher Scientific, Waltham,
MA, USA), BCL-2 (1:200-/#sc-7382, Santa Cruz Biotech-
nology, Heidelberg, Germany), Tubulin (1:2000-#sc-8035,
Santa Cruz Biotechnology, Heidelberg, Germany), Cleaved
Caspase-3 (1:500-/#9661, Cell Signaling Technology, Dan-
vers, MA, USA), Total Caspase-3 (1:1000-/#9662, Cell Sig-
naling Technology, Danvers, MA, USA), PARP-1 (sc-7150,
Santa Cruz Biotechnology, Heidelberg, Germany), RIP-1
(1:2000-/#610458, BD Biosciences, San Jose, CA, USA),
RIP-3 (1:2000-/#NBP2-24588, Novus Biologicals, Littleton,
CO, USA). Secondary antibodies were: Goat anti-mouse
IgG-HRP Santa Cruz Biotechnology, sc-2005; a-rabbit IgG-
HRP, Jackson, 111-035-003. All the antibodies were diluted
in 5 % skim milk”. Antibody signal was obtained with
the enhanced chemiluminescence plus Western blotting
detection system (Amersham Biosciences, Uppsala,
Sweden) after exposure to Kodak Super RX film. Values
were measured using the Image-Quant software (Amer-
sham Biosciences) and protein levels were normalized
against housekeeping proteins (tubulin/GAPDH). Ex-
periments were independently repeated three times and
standard deviation is presented.
Two dimensional culture
For the 2D culture experiments, cells (5×103 cells/well)
were grown on cover slips in 24-well plates in medium,
at 37 °C. Photographs of the 2D cultures were taken
under light and confocal microscope after the selected
treatments and appropriate staining.
The nuclei were stained with Hoechst No. 33342 (catalog
No. 62249, ThermoFisher Scientific, Waltham, MA, USA)
for apoptosis detection; the cleaved caspase-3, a marker of
apoptosis, was detected with cleaved caspase-3 antibody
(#9661, Cell Signaling Technology, Danvers, MA, USA)
and a fluorescent secondary antibody (Alexa Fluor 488,
#A11008, ThermoFisher Scientific, Waltham, MA, USA)
Three dimensional culture
For three-dimensional culture Matrigel (catalog No.
356234, BD Biosciences, San Jose, CA, USA) was used.
Poly-lysine pre-coated cover slips were put in 24-well
plate. Matrigel was diluted with cold complete DMEM
medium to a final concentration of 50 %, 200 μl were de-
posited on each well containing cover slips and the plate
was incubated at 37 °C for 15’. 1-1.5×103 cells was diluted
in 100 μL of cold DMEM and mixed with 100 μL of
100 % Matrigel. The resulting 200 μL were added to the
wells with pre-warmed Matrigel. Plate was incubated in a
humidified atmosphere at 37 °C with 5 % CO2 for 13–15
days. Photographs of the 3D cultures were taken under
light and confocal microscope after the selected treat-
ments and appropriate staining. The nuclei were stained
with Hoechst No. 33342 (catalog No. 62249, Thermo-
Fisher Scientific, Waltham, MA, USA) for apoptosis de-
tection; the cleaved caspase-3, a marker of apoptosis, was
detected with cleaved caspase-3 antibody (#9661, Cell Sig-
naling Technology, Danvers, MA, USA) and a fluorescent
secondary antibody (Alexa Fluor 488, #A11008, Thermo-
Fisher Scientific, Waltham, MA, USA)
Cell viability assay
For growth studies the sulforhodamine B (SRB) (S1402-5G,
Sigma-Aldrich, Taufkirchen Germany) assay was used.
Firstly, tumour cells (5×103 cells/well) were seeded into 96-
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well micro titer plates and were allowed to attach overnight.
Thereafter, the cell number in treated versus control wells
was estimated after treatment with 10 % trichloroacetic acid
and staining with 0.4 % SRB in 1 % acetic acid. The per-
centage of viable cell was plotted each time. SD was used
for error bar generation. For the calculation of combined
drug effects, the median effect analysis was used [27, 28].
Synergism was determined using the method previously de-
scribed based on the Bliss Independence Model [28, 29].
Cell migration assay
Cells were trypsinised, washed with medium contain-
ing 1 % FBS, and counted. 105 cells were plated into
upper chamber of an 8 μm-pore Transwell filter (#3422,
Corning, NY, USA), mounted in a 24-well dish containing
10 % FBS medium. Filters were pre-coated with Fibronectin
(f1141, Sigma-Aldrich, Taufkirchen, Germany). Cells were
allowed to migrate at 37 oC, 5 % CO2 for 36–40 h, fixed
with methanol and stained with 0.1 % w/v crystal violet.
Underside of filters was observed with 40× objective and
migrating cells were determined in ten randomly selected
fields for each well. Experiments were performed in dupli-
cate and repeated twice. For migration assay coupled with
SMAC-mimetic, cells were treated with Birinapant for 24
or 48 h and then seeded on transwell in the presence of Bir-
inapant and incubated at 37 °C for another 24 h.
RNA extraction, reverse transcription and real time-PCR
Total RNA isolation from cultured cells as well as cancer
specimens was performed using the Trizol reagent (Invitro-
gen, Karlsruhe, Germany). Reverse transcription was car-
ried out from 3.0 μg of purified RNA using the SuperScript
Reverse Transcriptase (Invitrogen, Karlsruhe, Germany) fol-
lowing the manufacturer’s instructions. Real-time quantifi-
cation at the mRNA level was carried out in 96-well PCR
plates using a Bio-Rad iCycler and the iQ5 Multicolor real-
Time PCR detection system (Bio-Rad, Hercules, CA, USA).
Each reaction contained 1× iQ SYBR Green Supermix
(Bio-Rad, Hercules CA, USA) and 150 nmol/L of each pri-
mer. All genes were tested in duplicates. Results were ana-
lyzed on the iCycler software. Values were normalized to
GAPDH. Primers used were the following:
GAPDH: 5’-GAA GGT GAA GGT CGG AGT (FW)
5’-CAT GGG TGG AAT CAT ATT GGA (RV)
cIAP-1: 5’-TGT TGT CA ACTT CAG ATA CCA CTG
G-3’ (FW)
5’-CAT CAT GAC AGC ATC TTC TGA AGA-3’ (RV)
cIAP-2: 5’-TCC GTC AAG TTC AAG CCA GTT-3’
(FW)
5’-TCT CCT GGG CTG TCT GAT GTG-3’ (RV)
XIAP: 5’-GAC AGT ATG CAA GAT GAG TCA AGT
CA-3’ (FW)
5’-GCA AAG CTT CTC CTC TTG GAG-3’ (RV)
BIRC5: 5’-GCA CGG TGG CTT ACG CCT G-3’ (FW)
5’-AAC CGG ACG AAT GCT TTT TAT CC-3’ (RV)
DR4: 5’-TCC AGC AAA TGG TGC TGA C-3’ (FW)
5’-GAG TCA AGG GGC ACG ATG TT-3’ (RV)
DR5: 5’-CCA GCA AAT GAA GGT GAT CC-3’ (FW)
5’-GCA CCA AGT CTG CAA AGT CA-3’ (RV)
Results
XIAP, DR4 and DR5 are overexpressed at the mRNA and
protein levels in all adenocarcinoma cell lines. High levels
of BCL-2 protein expressed in RKO cell line
Relative RNA levels of cIAP-1, cIAP-2, XIAP, SURVIVIN,
DR4 and DR5 genes were evaluated by Real Time PCR
analysis in seven colon cancer cell lines. Caco-2 is an
intermediate adenoma cell line and was used as control.
The other six cell lines are colorectal adenocarcinoma cell
lines: DLD-1 and HCT116 bear KRAS and PI3KCA muta-
tions, SW620 bears KRAS mutation, HT29 and RKO bear
BRAF and PI3KCA mutations and Colo205 cell line bears
BRAF mutation.
XIAP mRNA is overexpressed in all adenocarcinoma
cell lines as compared to Caco-2, mostly in SW620 (over
6-fold) (Fig. 1a, lane 4) and in HT29 and Colo205 (up to
4-fold) (Fig. 1a, lanes 5 and 7, respectively). Protein levels
of XIAP were also found up-regulated in all cell lines
compared to Caco-2 and especially in SW620 (2.8-fold)
(Fig. 1a, lane 4), in HT29 (2.1-fold), in HCT116 and
Colo205 (1.9-fold) and in DLD-1 (1.8-fold) (Fig. 1a, lanes
5, 3, 8 and 2 respectively).
TRAIL receptors expression was evaluated by Q-PCR
and western blot analysis: DR4 mRNA is mostly over-
expressed in HCT116 and RKO (4-fold), as well as in
SW620 and Colo205 (up to 3-fold) compared to Caco-2
respectively (Fig. 1a. lanes 3, 6, 4, and 7). On the other
hand, protein levels of DR4 were found over-expressed
in all cell lines. In HT29 cell line by 3.9 fold, in Colo205
by 3.2 fold, in RKO by 2.8 fold, in SW620 by 2.4 and in
DLD-1 by 2.3 fold compared to Caco-2 intermediate ad-
enoma cell line respectively (Fig. 1a, lanes 5, 7, 6, 4, 2).
DR5 mRNA was also found over-expressed in all cell
lines as compared to Caco-2, mostly in RKO (2.5-fold),
as well as in HCT116 and SW620 (2-fold) cell lines
compared to Caco-2 (Fig. 1a, lanes 6, 3, 4 respectively).
Protein levels of DR5 were detected remarkably up-
regulated in all cell lines compared to Caco-2: from 5.7-
fold in HCT116 to 1.8-fold in RKO, as compared to
Caco-2 cell line (Fig. 1a).
mRNA levels of cIAP-1 and cIAP-2 have no significant
differences between Caco-2 and adenocarcinoma cell
lines, while cIAP-2 protein was over-expressed in all cell
lines compared to Caco-2 (Fig. 1a). mRNA level of SUR-
VIVIN is overexpressed in all cell lines but mostly in
HCT116 as compared to Caco-2 (Fig. 1a). On the other
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hand, most of examined BCL-2 family members involved
in the intrinsic death pathway were found over-
expressed in almost all adenocarcinoma cell lines uti-
lized: BCL-2 protein in RKO cell line being the most up-
regulated, other overexpressed factors of this family are
BAK and BAX (Fig. 1b).
Treatment with SMAC-mimetics Birinapant and AT-406
resulted in a decrease of cell viability and appearance of
apoptotic characteristics in colorectal adenocarcinoma
cells
The effect of IAP inhibitors on colorectal adenocarcinoma
cell lines was examined by cell treatments with SMAC-
a
b
Fig. 1 Overexpression of IAP members, TRAIL receptors DR4, DR5 and BCL-2 members in colorectal adenocarcinoma cell lines: DLD-1 (lane 2),
HCT116 (lane 3), SW620 (lane 4), HT29 (lane 5), RKO (lane 6) and Colo-205 (lane 7), compared to Caco2, an intermediate colorectal adenoma cell
line (lane 1). a: Relative RNA and protein levels of cIAP-1, cIAP-2, XIAP, SURVIVIN, DR4 and DR5 genes were evaluated by Real Time PCR and W.B
analysis respectively in colon adenocarcinoma cell lines. The analysis was performed in triplicates and the ± SD is shown. Columns indicate relative
RNA levels normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Proteins are quantified against α-Tubulin. b: Protein levels of
other (anti)apoptotic factors in colon adenocarcinoma cell lines by W.B. Data are representative for three independent experiments
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mimetics Birinapant or AT-406 in RKO and HCT116
colorectal adenocarcinoma cell lines. Up to 50 % decrease
of cell viability in RKO cell line after 72 h treatment with
the SMAC-mimetic Birinapant in several doses was ob-
served (Fig. 2a, lower panel), while shorter treatment
(48 h) resulted in 25–30 % reduction of cell viability of
RKO cells (Fig. 2a, upper panel).
Following the above findings regarding reduction of
cell viability after Birinapant treatment, the effect of
SMAC-mimetics treatments on apoptosis was tested.
After 72 h treatment of RKO cells with 0.5–5 μM Birina-
pant, clear signs of apoptosis were detected, as shown by
caspase-3 and PARP-1 cleavage (Fig. 2b, lanes 6, 7, 8)
and by detection of fragmented nuclei in RKO cells
(Fig. 2c, lower panel). On the other hand, AT-406
treatment in RKO cells resulted in a lower reduction of
cell viability (15–20 %), as compared to Birinapant, while
little effect on apoptotic markers like PARP-1 cleavage,
caspase-3 cleavage (Fig. 2b, lanes 3–5), was detected,
further confirmed by small number of crescent nuclei
(Fig. 2c, middle panel). Parallel treatments of Birinapant
and AT-406 in HCT116 cell line, resulted in no signifi-
cant effects on either cell viability (Fig. 2a) or apoptotic
markers (Fig. 2b and d), respectively
Birinapant treatment results in the reduction of cell
migration properties of RKO cell line
Since IAPs were shown to be involved in cell migration
[1], their potential effect of their inhibition on cell migra-
tion properties in colorectal adenocarcinoma cells was
a b
c d
Fig. 2 Birinapant treatment results in reduced cell viability and appearance of apoptosis in selected colorectal adenocarcinoma cells. a: Cell
viability of cell lines after treatment with SMAC-mimetics. Cells were either left untreated (ctr = control) or treated with 0.5 μM, 1 mM or 5 mM AT-406
and Birinapant for 48 h (1) and 72 h (2) and the % percentage cell viability was measured by SRB. Average of three independent experiments are
presented as fold change of the absorbance of treated/untreated cells for each condition. Columns =% percentage of cell viability, bars = SD. b: Protein
levels of XIAP, cIAP-1, PARP-1 and total caspase-3 in RKO and HCT116 were analysed by W.B. after treatment with 0.5, 1 and 5 μM SMAC-mimetics AT-406
(lanes 3–5) and Birinapant (lanes 6–8) for 48 and 72 h. Untreated (lane 1) or treated with DMSO cells (lane 2) were used as control. Proteins are quantified
against α-Tubulin. Data are representative for three independent experiments. c-d: Confocal microscope images and Hoechst staining of RKO (2C) and
HCT116 (2D) cell lines two-dimensional culture, after treatment with SMAC-mimetics AT-406 (A) and Birinapant (B). Crescent nuclei of RKO cells present
after cell treatments are shown by arrows. Confocal microscope images were taken after treatment with SMAC-mimetics AT-406 and Birinapant in RKO
(2c) and HCT116 (2d) 48 and 72 h. The nuclei were detected with HOECHST staining. Representative images are presented
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tested (Fig. 3, upper panel). Indeed, after 48 or 72 h treat-
ment with 0.5 μM, 1 μM and 5 μM SMAC-mimetics Biri-
napant or AT-406, less migrative cells were detected, as
compared to the untreated cells (Ctr), which was more
evident with Birinapant treatments in all doses (Fig. 3,
upper panel). Cell numbers after the corresponding treat-
ments are presented in Fig. 3, lower panel. As indicated
here, Birinapant and to a less extent AT-406, have shown
potency towards colorectal adenocarcinoma cell death
and inhibition of cancer cell migration properties.
The mild treatment effects of the tested SMAC-
mimetics presented in the first part of this study, pro-
posed for rational combined treatment protocols in
resistant cell lines to overcome resistance. Co-
treatments presented in the following second part of
the study include rational combinations of SMAC
mimetics with a) oncogenic BRAFV600E inhibitors,
also not efficient as mono-treatments, b) other thera-
peutics targeting apoptosis, like TRAIL and c) BCL-2
inhibitors, in cells presenting high BCL-2 expression.
SMAC-mimetics synergise with BRAFV600E inhibitor
towards efficient antitumour treatments in 3D cultures of
colorectal adenocarcinoma cells
RKO colon adenocarcinoma cells were partially resist-
ant to SMAC-mimetics Birinapant and AT-406, as
shown in previous experiments (Fig. 2a). Moreover, it
has been shown in many studies and clinical trials that
colorectal tumours and cell lines are resistant to spe-
cific BRAFV600E inhibitors PLX4720 and PLX4032
(Vemurafenib). Therefore, the potential synergy of Biri-
napant or AT-406 with PLX4720 in killing colorectal
cancer cells was tested. Co-treatments of Birinapant
with PLX4720 did not improve the efficiency of individ-
ual mono-treatments (Fig. 4a). Notably, a synergistic ef-
fect in the reduction of cell viability of RKO cell line
was observed after applying a treatment protocol in-
volving Birinapant pre-treatment and then combined
treatment of Birinapant with PLX4720 for 48 and 72 h:
as a result 49 and 48 % synergistic reduction of cell via-
bility in RKO cells respectively was reported, 8 and 9 %
more than the sum of the mono-treatments of Birina-
pant and PLX4720 at the same time points respectively
(Fig. 4b). The above combined protocol using Birina-
pant pre-treatment, followed by Birinapant-PLX4720
co-treatment have caused the appearance of apoptotic
markers in RKO cells, like PARP-1 cleavage after 48 h
(Fig. 4c, lanes 7–10). Further evidence is provided by
light microscopy images, where the detached RKO cells
after this combined treatment are shown, especially
after 72 h combined treatment (Fig. 4d, right panel).
Ex vivo conditions which can mimic the in vivo
Fig. 3 Birinapant treatment reduces RKO tumour cell migrative capacity. Upper panel: Migration ability of RKO cell lines treated with
SMAC-mimetics AT-406 and Birinapant compared to the untreated cells. Cells were treated with AT-406 and Birinapant for 24 or 48 h and
allowed to migrate. The values are the average of two independent experiments. Lower panel: Cell proliferation of cell line RKO co-treated
with SMAC-mimetics AT-406 and Birinapant for 48 and 72 h. The values are the average of two independent experiments. Columns =
number of cells/well (of 6-well plate)
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Fig. 4 (See legend on next page.)
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environment can be provided by 3D culture treatments.
In 3D culture, a disorganization of some of the tumour
colonies was detected (Fig. 4e, lower panel) and higher
staining of cleaved caspase-3 was observed (Fig. 4f )
after the combined treatment of Birinapant and
PLX4720 for 6 days. A minor effect on cell properties
using these two assays was shown during 3D culture
mono-treatments (Fig. 4e and f ). Finally, the combined
treatment of the other SMAC-mimetic AT-406 with
PLX4720 did not provide any advantage in the reduc-
tion of RKO tumour cell viability, as compared to
mono-treatments (Additional file 1: Figure S3).
Treatment with SMAC-mimetics Birinapant and AT-406
can sensitize resistant-to-TRAIL cancer cells to apoptosis
in 2D and 3D cell cultures
As HT29 (mainly) and RKO cell lines appear partially
resistant to TRAIL [27, 28] and has shown little re-
sponse to Birinapant, we decided to check if the com-
bined treatment of these two drugs would be more
efficient in killing HT29 and/or RKO cells. Combined
treatments of Birinapant and TRAIL for 48 or 72 h re-
sulted in up to 90 % significant reduction of cell viability
in HT29, a cell line that appears partially resistant in
TRAIL-induced apoptosis (Fig. 5a). Combined treat-
ments of Birinapant and TRAIL in RKO resulted in re-
duction of cell viability up to more than 85 % compared
to the untreated cells, or those which were mono-
treated, both at 48 or 72 h (Fig. 5a-RKO, upper panel).
Notably, under these conditions, the effect of combined
Birinapant and TRAIL treatments on RKO cell viability
was irreversible after additional cell incubation without
drug, which was not the case in the mono-treatments
(Fig. 5a-RKO, lower panel, lane 8 compared to 1, 2, 3
and 5). Combined treatments of Birinapant with TRAIL
not only decreased cell viability in both cell lines, but re-
sulted in clear appearance of apoptotic markers, like
PARP-1 and caspase-3 cleavage (Fig. 5b-II and 5b-III,
lanes 7–9 and Fig. 5b-III- RKO, lanes 11–13) as com-
pared to non-treated cells (lanes 1, 2), or mono-treated
cells (lanes 3 and 4–6). HCT116 cells treated with
TRAIL were used as positive control of apoptosis (lane
10). Efficiency of Birinapant combined treatments can be
due to the effect of 0.5, 1 and 5 mM Birinapant treat-
ment on the reduction of XIAP protein levels after 48 h
(Fig. 5b-I, lanes 6–8 respectively compared to control
lane 1), although the effect on cell viability are not opti-
mal under the same conditions. In other words, Birina-
pant treatment may prime HT29 cells to TRAIL induced
cell death by reducing XIAP expression levels. In RKO
cell line there is no evident reduction of XIAP levels
after 24 h (Fig. 5b-I-RKO) or 48 h (data not shown).
Additional evidence for the TRAIL-Birinapant combined
treatment efficiency in HT29 cells was provided by light
microscopy images, showing detached HT29 cells after
48 or 72 h TRAIL-Birinapant combined treatments
(Fig. 5c, left or right panel respectively), while confocal
microscopy images indicated the fragmented (apoptotic)
nuclei and cleaved caspase-3 distribution in a number of
treated tumour cells (Fig. 5d). Lower concentration of
Birinapant (0.5 μM and 1 μM) in combination with
TRAIL did not show any synergistic effect on HT29
tumour cell viability (Additional file 2: Figre S2a and
S2b), but a higher concentration of Birinapant (10 μM)
presented similar synergistic effect in combination with
TRAIL, as with the lower concentrations 0.5–5 μM
(Additional file 2: Figure S2c). As shown here, the effect
of combined Birinapant and TRAIL treatments on RKO
cell viability was synergistic and irreversible.
In order to provide further evidence of Birinapant-
TRAIL efficiency, co-treatment protocols were tested
in models involving tumour microenvironment, like
3D tumour cell cultures: a significant reduction of
tumour size and disorganization (Fig. 5e) and higher
staining of cleaved caspase-3, as shown in confocal
microscopy images (Fig. 5f ) was detected after the
(See figure on previous page.)
Fig. 4 Pre-treatment with Birinapant and then co-treatment with Birinapant/ BRAF inhibitor PLX4720 synergistically induce apoptosis of colorectal
adenocarcinoma cells in 2D and 3D. a: Cell viability after co-treatment with the SMAC-mimetics Birinapant or AT-406 in combination with the BRAF
inhibitor PLX4720. Cells were either left untreated (ctr = control) or treated with 5 μM Birinapant, 5 μM AT-406 and 1 μM PLX4720 and their combina-
tions for 48 and 72 h. The average of three independent experiments is presented as fold change of the absorbance of treated/untreated cells, for each
condition. Columns =% percentage of cell viability, bars = SD. b: Cell viability after pre-treatment with the SMAC-mimetic Birinapant and then co-
treatment with BRAF inhibitor PLX4720 and Birinapant. Cells were either left untreated (ctr = control) or treated with 0.5 or 1 μM Birinapant and 0.2 or
0.5 μM PLX4720. For the pre-treatment testing, cells were first incubated for 24 h with either 0.5 or 1 μM of Birinapant and then co-treated with 0.2
and 0.5 μM PLX4720 for another 24 or 48 h. c: Protein levels of PARP-1, total Caspase-3, XIAP, cIAP-1 and p-ERK1/2 in RKO by W.B., after pre-treatment
with 0.5 or 1 μM Birinapant and then co-treatment with 0.2 or 0.5 μM PLX4720. Untreated cells were used as control. Proteins are quantified against α-
Tubulin. Data are representative for three independent experiments. d: Light microscopy images from RKO culture after pre-treatment with Birinapant
and then co-treatment with PLX4720. Detached cells are shown in supernatant of co-treated group. Several images were taken from untreated and
treated with Birinapant (0.5 or 1 μM) and PLX4720 (0.2 or 0.5 μM) RKO cells while been cultured in 6-well plates for 48 and 72 h. Representative images
are presented. e: Light microscopy of three-dimensional culture of RKO cells after co-treatment with 0.5 μM, 1 μM Birinapant and 0.2 μM, 0.5 μM
PLX4720 and their combination in 3D culture for 6 d. Representative images. f: Confocal microscope images were taken after co-treatment with
0.5 μM, 1 μM Birinapant and 0.2 μM, 0.5 μM PLX4720 and combinations in 3D cultures for 6 days. The nuclei were detected with HOECHST staining
(blue color), cleaved Caspase-3 (green color). Representative images. Scale bar: 20 μm
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combined treatment of Birinapant and TRAIL for
6 days. Effects after mono-treatments of individual
drugs were also detected.
Furthermore, the efficiency of combined treatment with
the SMAC-mimetic AT-406 and TRAIL in killing HT29
and RKO cells was tested. Similar synergistic effect is
Fig. 5 Co-treatment of Birinapant with TRAIL can synergistically increase their efficiency and induce apoptosis in colorectal adenocarcinoma cells
in 2D and 3D. 5a: Cell viability of cell line HT29 after co-treatment with the SMAC-mimetic Birinapant and the apoptotic agent TRAIL. Cells were
either left untreated (ctr = control) or treated with Birinapant, TRAIL and their combination for 48 and 72 h and the % percentage cell viability
was measured. The average of three independent experiments is presented. Columns = % percentage of cell viability, bars = SD. 5a-RKO: Respect-
ively for cell line RKO (upper panel). To check for the reversibility of treatment effects, RKO cells were either left untreated (ctr = control), treated
with either Birinapant, TRAIL or their combination for 48 h. Cells were then incubated with additional 48 h without treatments (NoT) and the %
percentage cell viability was measured. The average of three independent experiments is presented. 5b-I. Protein levels of cIAP-1 and XIAP after
0.5, 1 and 5 μM AT-406 (lanes 3–5) or Birinapant (lanes 6–8) treatments respectively for 48 h, compared to control lanes 1 (no treatment) or 2
(DMSO treatment). 5b-II and 5b-III. Protein levels of PARP-1 and total Caspase-3 in HT29 cell line after co-treatment with SMAC-mimetic Birinapant
and TRAIL for 48 and 72 h. Cells were either left untreated (lane 1) or treated with DMSO (lane 2), with 5 μM Birinapant (lane 3), with 10, 50 and
100 ng/mL TRAIL (lanes 4–6), or with 5 μM Birinapant and combination with TRAIL (lanes 7–9) for 48 and 72 h. Sensitive cell line HCT116 treated
with TRAIL is used as positive control (lane 10). Using W. B., protein levels of PARP-1 (Figure 5b-II) and of total Caspase 3 (Figure 5b-III) were analyzed after
the corresponding treatments. Data are representative for three independent experiments. 5b-I-RKO: Protein levels of cIAP-1 and XIAP after mono-
treatments (lanes 3 and 4 for AT-406 and Birinapant respectively and lanes 5–7 for TRAIL 10, 50 and 100 ng/mL respectively) and co-treatments (lanes 8–13
as shown) for 24 h. Untreated (lane 1) and treated with DMSO (lane 2), cells are also presented. 5b-II-RKO and 5b-III-RKO: Protein levels of PARP-1 and total
Caspase-3 after respective mono-treatments and co-treatments (same lines as 5-I-RKO). Data are representative of three independent experiments. 5C: Light
microscopy images from HT29 culture after combined treatment with Birinapant and TRAIL. Detached (apoptotic) cells are shown in supernatant of co-
treated groups for 48 and 72 h. Representative images. 5d: Confocal microscope images were taken after co-treatment with Birinapant, TRAIL and their
combination. Nuclei were detected with HOECHST staining (blue color), cleaved Caspase-3 (green color). Representative images.. Scale bar: 9.9 μm. 5e. Light
microscopy of three-dimensional culture of HT29 cells after co-treatment with Birinapant, TRAIL and their combinations in 3D for 6 days. Representative
images. 5f: Confocal microscope images were taken after co-treatment with Birinapant, TRAIL and their combinations in 3D culture for 6 days. The nuclei
were detected with HOECHST staining (blue color), cleaved Caspase-3 (green color). Representative images. Scale bar: 57.4 μm
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shown after AT-406 and TRAIL combined treatment of for
48 or 72 h in HT29 but not in RKO cells. A reduction up
to 60 % of tumour cell viability was detected (Fig. 6a). The
combined treatment with AT-406 and TRAIL resulted in
cleavage of caspase-3 after 72 h treatment, in HT29 cells, as
shown by confocal microscopy images (Fig. 6b).
The synergistic effects first presented above were also
formally validated (Fig. 7) using the equation DeltaGI =
GITRAIL + GIBirinapant(or GIAT-406)-GIcombination, based on
the Bliss Independence Model. In this model, values
below zero indicate synergism. The cells were mono-
treated with a fixed dose of Birinapant or AT-406 (5 μM
in HT29 and 1 μM in RKO, because of their differential
sensitization to SMAC-mimetics) and increasing con-
centrations of TRAIL (100 to 0,78125 ng/mL), as well as
co-treated with the fixed dose of Birinapant and different
TRAIL concentrations for 48 and 72 h. Synergistic ef-
fects in HT29 cells clearly appeared in treatments in-
volving either of the two SMAC-mimetics at 48 and
72 h (Fig. 7a). The best synergistic effect was delivered
by the combination of 5 μM Birinapant and 3.125 ng/
mL TRAIL (*) which is up to -75 Delta GI. In RKO cell
line instead, only Birinapant treatments show synergistic
effects when combined with specific TRAIL concentra-
tions (Fig. 7b).
ABT-199, a specific inhibitor of BCL-2, reduces cell viabil-
ity and has synergistic effect with SMAC-mimetics Birina-
pant and AT-406 in RKO tumour cells
A notable overexpression of BCL-2 in RKO cell line is
shown in Fig. 1c, therefore a specific BCL-2 inhibitor ABT-
199 was used to test the importance of BCL-2 over-
expression in RKO cell line viability and aggressiveness.
ABT-199 treatment for 48 and 72 h resulted in reduction of
RKO tumour cell viability, up to 60 and 80 % respectively, in
concentrations 5–20 μM (Fig. 8a). Since RKO tumour cells
appeared partially resistant to ABT-199 treatments, com-
bined treatments of ABT-199 with SMAC-mimetics AT-406
or Birinapant were tested for potential improved efficacy.
The co-treatment protocol of ABT-199 with AT-406
Fig. 6 SMAC-mimetic AT-406 and TRAIL synergistically kill resistant tumour cells. 6a Cell viability of HT29 cell line after combined treatment with
SMAC-mimetic AT-406 and the apoptotic agent TRAIL. Cells were either left untreated (ctr = control) or treated with AT-406 combined with TRAIL for
48 and 72 h and the % percentage cell viability was measured by SRB staining. The values are the average of three independent experiments and are
presented as fold change of the absorbance of treated/untreated cells, for each condition. Columns =% percentage of cell viability, bars = SD. 6a-RKO:
Respectively for cell line RKO. 6b. Confocal microscope images were taken after co-treatment with AT-406, TRAIL and their combinations for 48 and
72 h. The nuclei were detected with HOECHST staining (blue color), cleaved Caspase-3 (green color). Representative images. Scale bar: 9.9 μM
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resulted in an enhanced effect on RKO tumour cell viability
after 48 and 72 h, as compared to mono-treatments under
the same conditions (Fig. 8b). Most notably, combined treat-
ments of ABT-199 with Birinapant indicated a synergistic
effect on RKO cell viability after 48 h treatment, as shown
in Fig. 8c. Thus, in tumour cells with high BCL-2 expres-
sion, targeting apoptosis by combined protocols of BCL-2
with IAP inhibitors can provide efficient anti-cancer treat-
ments in a synergistic manner.
Discussion
The present study investigates the efficiency of SMAC-
mimetics Birinapant and AT-406 in a number of CRC
cell lines. Oncogenic and apoptotic pathways are
exploited towards establishing novel as well as efficient
anti-cancer treatment protocols, which involve either
Birinapant or AT-406 as single agents or their rational




Fig. 7 SMAC-mimetics AT-406 and Birinapant show synergistic effects when co-treated with TRAIL in HT29 and RKO. 7a-HT29: Synergy graphs for
HT29 cell line treated for 48 and 72 h with AT-406 or Birinapant fixed dose (5 μM) and increasing concentrations of TRAIL (from left to right: 100,
50, 25, 12,5, 6,25, 3,125, 1,5625 and 0,78125 ng/mL). 7b-RKO: Respectively for RKO cell line with fixed dose of SMAC-mimetics 1 μM
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Fig. 8 BCL-2 inhibitor ABT-199 can efficiently cause apoptosis when combined with SMAC-mimetics Birinapant and AT-406. a: Cell viability of RKO after
treatment with ABT-199, a specific inhibitor of BCL-2. Cells were either left untreated (ctr = control) or treated with different concentrations of ABT-199
for 48 and 72 h and the % percentage cell viability was measured by SRB. The values are the average of three independent experiments and are
presented as fold change of the absorbance of treated/untreated cells, for each condition. Columns =% percentage of cell viability, bars = SD.
b: Cell viability of cell line RKO after combined treatment with the SMAC-mimetic AT-406 and ABT-199. Cells were either left untreated (ctr = control) or
treated with AT-406 combined with ABT-199 for 48 and 72 h and the % percentage cell viability was measured by SRB. c: Cell viability of cell line RKO
after combined treatment with the SMAC-mimetic Birinapant and ABT-199. Cells were either left untreated (ctr = control) or treated with Birinapant
and ABT-199 combination for 48 and 72 h. The values are the average of three independent experiments and are presented as fold change of the
absorbance of treated/untreated cells, for each condition. Columns =% percentage of cell viability, bars = SD
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Expression levels of IAPs, DRs and BCL-2 may guide for
tailored targeted therapeutics
Analysis of expression levels of apoptotic factors in sev-
eral colorectal (CRC) adenocarcinoma cell lines provides
evidence for their potential importance as tumour
markers and/or targets, complimenting previous reports.
XIAP, DR4 and DR5 are overexpressed at the mRNA
and protein levels in all adenocarcinoma cell lines. Not-
ably, high levels of BCL-2 protein are detected in RKO
adenocarcinoma cell line. This data were further
exploited here towards developing rational and efficient
preclinical protocols based on the oncogenic and apop-
totic profile of the tumour cell lines.
Birinapant and AT-406 show a mild effect on CRC tumour
cells as mono-treatments
Treatment of a panel of CRC cell lines with novel
SMAC-mimetics Birinapant and AT-406 resulted in a
decrease of cell viability and cell migration properties, as
well as appearance of apoptotic characteristics of se-
lected colorectal adenocarcinoma cells, like the aggres-
sive RKO cells. Regarding cell migration, IAPs can
directly control Rho GTPases, thus regulating cell shape
and migration (1). Here, for the first time, reduction of
cancer cell migration by Birinapant is reported.
This study provides further evidence and interest on
Birinapant, a novel SMAC-mimetic and promising anti-
cancer agent [30] and its recently published proof of
mechanism data for quantifying apoptotic biomarkers in
clinical trials [31]. On the other hand, the mild treat-
ment effects of the tested SMAC-mimetics propose for
their rational combined treatment protocols in resistant
cell lines, either with BRAFV600E inhibitors or with
other therapeutics targeting apoptosis like TRAIL or
BCL-2 inhibitors.
Combined treatments of SMAC mimetics with BRAF
inhibitor sensitise resistant BRAFV600E Colorectal tumour
cells
BRAFV600E Colorectal tumours show intrinsic resist-
ance to BRAFV600E specific inhibitors Vemurafenib
and Dabrafenib (13), otherwise very efficient against
BRAFmut melanoma (12). Many studies, including the
current, aim at improving the efficiency of Vemurafenib
against colorectal tumours by rational combined
treatments.
Here, SMAC-mimetics Birinapant and AT-406 can syner-
gise with PLX4720, a Vemurafenib lead compound, towards
efficient antitumour treatments of BRAFV600E colorectal
adenocarcinoma cells in 2D and 3D cultures. It is of inter-
est, that the successful protocol includes pretreatment with
Birinapant with subsequent Birinapant- PLX4720 combined
treatment, which is necessary for tumour cell death to be
induced.
These results support the therapeutic combination
of Birinapant with multiple chemotherapies, as shown
for those therapies that can induce TNF secretion
[34]. Remarkably, recent studies have provided strong
evidence that Birinapant co-treatment can overcome
platinum resistance in a tumour-initiating subpopula-
tion of ovarian cancer [35], as well as in a tumour-
initiating AML subpopulation in combination with
demethylating agents [36].
TRAIL can synergise with SMAC mimetics to efficiently
drive resistant tumour cells to apoptosis
Despite the fact that during colorectal carcinogenesis a
marked increase in sensitivity to TRAIL has been re-
ported, colorectal adenocarcinomas like HT29 and RKO
remain partially resistant to TRAIL-induced apoptosis
[37]. TRAIL resistance has been associated with defect-
ive ceramide signalling [38, 39]. Among the many stud-
ies of efficient combined treatments in colorectal cancer
cells involving TRAIL: quercetin can enhance TRAIL-
mediated apoptosis in colon cancer cells by inducing the
accumulation of death receptors in lipid rafts [32] and
the selective BRAF V600E inhibitor PLX4720 acts syner-
gistically with TRAIL in order to overcome oncogenic
PIK3CA resistance in colon cancer cells [33].
Here, treatment with SMAC-mimetics Birinapant and
AT-406 can sensitize resistant-to-TRAIL and SMAC-
mimetics HT29 cancer cells to apoptosis in 2D and 3D cul-
tures. The combination of Birinapant and TRAIL leads to
simultaneous activation of both the intrinsic and the extrin-
sic pathway. The same synergistic effect has been shown in
the combined treatment of AT-406 and TRAIL. Inhibiting
IAP function by SMAC-mimetics can apparently sensitise
the HT29 TRAIL resistant cell line to TRAIL-Birinapant
(or AT-406) combined treatments. These results are com-
plementing those of other studies [40], where Birinapant in
combination with TNF-a exhibits a strong anti-melanoma
effect in vitro and enhances TRAIL potency in inflamma-
tory breast cancer cells in an IAP-dependent and TNF-α-
independent mechanism [41].
Combined targeting of apoptosis at the BCL-2 and IAPs
level is efficient for CRC cells
Early in this study, expression analysis of apoptotic fac-
tors in the panel colon adenocarcinoma cell lines has
provided evidence for a notable overexpression of BCL-2
in RKO cell line. Therefore treatments with ABT-199, a
specific inhibitor of BCL-2 were performed, which re-
sulted in reduction of cell viability in RKO cell line.
ABT-199 is shown here to act synergistic with SMAC-
mimetics Birinapant and AT-406 on cell viability of RKO
colon adenocarcinoma cells. ABT-199 selectively targets
BCL-2 not BCL-XL and is active as a single agent in
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lymphoid malignancies such as CLL and non-Hodgkin
lymphoma [31].
Recently, a very efficient synergistic protocol of BRAF
with autophagy inhibitors in colorectal cancer cells has
been presented, as another example of the advantages
and better efficiency of rational combined treatments as
compared to mono-treatments [42].
Conclusions
Efficient protocols of inhibition of IAPs activity and
anti-apoptotic effect are presented by using Birinapant
or AT-406 alone and in their combinations with either
TRAIL (Figs. 5, 6 and 7) or with other inhibitors of pro-
survival pathways, like BRAF-MEK (Fig. 4) and BCL-2
(Fig. 8). Synergistic rational anticancer combined proto-
cols are presented depending on the tumour cell back-
ground, like resistance to individual treatments, BRAF
mutation or BCL-2 overexpression. These rational com-
bined treatments of agents targeting the tumour cell
apoptotic machinery to restore some of its functions lost
in cancer, can lead to efficient anti-cancer protocols,
once further validated at the pre-clinical level and finally
in the clinic.
Additional files
Additional file 1: Figure S3. Combined treatment of the other SMAC-
mimetic AT-406 with PLX4720. (TIF 1.89 mb)
Additional file 2: Figure S2a and Figure S2b. Treatments of
Birinapant (0.5μΜ and 1μΜ) in combination with TRAIL on tumour cell
viability. Figure S2c. Birinapant (10μΜ) synergistic effect in combination
with TRAIL. (TIF 2.64 mb)
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